维泰醇和维康醇的抗肿瘤效应

doi:10.3760/cma.j.issn.1673-422X.2017.06.013

摘要/Abstract

摘要： 维泰醇和维康醇是从真菌诱变株的菌丝体中提取纯化的单体化合物，近年的体外和体内实验研究证实它们具有特异性抗肿瘤功效。体外实验研究表明，它们可以抑制多种肿瘤包括前列腺癌、骨肉瘤、黑色素瘤的细胞分裂和增殖，改变细胞周期蛋白表达水平而引起细胞周期停滞，阻断肿瘤细胞浸润和转移，减少新生血管形成，降低肿瘤细胞中Bcl2等促进细胞存活蛋白的表达以及激发细胞内氧自由基水平等导致细胞凋亡，但是对良性细胞没有显著的致死效应。动物实验表明，这两种化合物能显著抑制多种人类肿瘤的异植瘤生长，而对正常组织器官的不良反应较小，有望开发成为新型抗肿瘤药物。

关键词: 肿瘤, 细胞凋亡, 细胞周期, 维泰醇, 维康醇

Abstract: Alternol and Alteronol are two small chemical compounds purified from a mutant fungal. The in vitro and in vivo experimental studies have confirmed their potent anticancer effect. In vitro studies show that they can inhibit cell division and proliferation of a variety of tumors including prostate cancer, osteosarcoma and melanoma. They exert their anticancer effects by attenuating cell cycle protein expression and causing cell cycle arrest, suppressing tumor cell invasion and metastasis, reducing new blood vessel formation, decreasing the expression of antiapoptotic proteins Bcl2 in malignant cells, and stimulating oxygen free radical accumulation. However, there is no significant cytotoxic effect on benign cells. Animal experiments show that these two compounds significantly inhibit xenograft growth derived from a variety of human malignant tumors, while there is no obvious side effect on normal tissue or organs. In conclusion, these two compounds are worthy to be developed as novel anticancer drugs.

Key words: Neoplasms, Apoptosis, Cell cycle, Alternol, Alteronol

刘丽华，李本义. 维泰醇和维康醇的抗肿瘤效应[J]. 国际肿瘤学杂志, 2017, 44(6): 452-.

Liu Lihua, Li Benyi. Anti-cancer effects of Alternol and Alteronol on human cancers[J]. Journal of International Oncology, 2017, 44(6): 452-.

参考文献

［1］ Wani MC, Taylor HL, Wall ME, et al. Plant antitumor agents. Ⅵ. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia［J］. J Am Chem Soc, 1971, 93(9): 2325-2327. ［2］ Chen JP, Duan LL, Wang R, et al. Microorganism for producing the novel compound: US, 20090203775A1［P］. 20090813. ［3］ Duan LL, Chen H, Chen JP, et al. The fermentation process of the new anticancer compound Alternol［J］. J Shenyang Pharma Univ, 2009, 26(4): 316-323. ［4］ Liu ZZ, Zhu J, Sun B, et al. Alternol inhibits proliferation and induces apoptosis in mouse lymphocyte leukemia (L1210) cells［J］. Mol Cell Biochem, 2007, 306(1/2): 115-122. DOI: 10.1007/s1101000795600. ［5］ Liu ZZ, Chen JP, Zhao SL, et al. Apoptosisinducing effect of alternol on mouse lymphocyte leukemia cells and its mechanism［J］. Yao Xue Xue Bao, 2007, 42(12): 1259-1265. ［6］ Liu X, Wang J, Sun B, et al. Cell growth inhibition, G2M cell cycle arrest, and apoptosis induced by the novel compound Alternol in human gastric carcinoma cell line MGC803［J］. Invest New Drugs, 2007, 25(6): 505-517. DOI: 10.1007/s1063700790574. ［7］ Cong PF, Qu YC, Chen JP, et al. Growth inhibition and apoptosis induction by alternol in pancreatic carcinoma cells［J］. World J Gastroentero, 2015, 21(15): 4526-4535. DOI: 10.3748/wjg.v21.i15.4526. ［8］ Zhu XL, Wang YL, Chen JP, et al. Alternol inhibits migration and invasion of human hepatocellular carcinoma cells by targeting epithelialtomesenchymal transition［J］. Tumour Biol, 2014, 35(2): 1627-1635. DOI: 10.1007/s132770131224y. ［9］ Yeung ED, Morrison A, Plumeri D, et al. Alternol exerts prostateselective antitumor effects through modulations of the AMPK signaling pathway［J］. Prostate, 2012, 72(2): 165-172. DOI: 10.1002/pros.21417. ［10］ Tang Y, Chen R, Huang Y, et al. Natural compound Alternol induces oxidative stressdependent apoptotic cell death preferentially in prostate cancer cells［J］. Mol Cancer Ther, 2014, 13(6): 1526-1536. DOI: 10.1158/15357163.MCT130981. ［11］ Zuo D, Zhou Z, Wang H, et al. Alternol, a natural compound, exerts an antitumour effect on osteosarcoma by modulating of STAT3 and ROS/MAPK signalling pathways［J］. J Cell Mol Med, 2017, 21(2): 208-221. DOI: 10.1111/jcmm.12957. ［12］ Yao Y, Zhang B, Chen H, et al. Alteronol inhibits proliferation in HeLa cells through inducing a G1phase arrest［J］. J Pharm Pharmacol, 2012, 64(1): 101-107. DOI: 10.1111/j.20427158.2011.01375.x. ［13］ Su X, Gong P, Wang D, et al. Effect of alternol on the anticancer of mouse cervical carcinoma U14 cells［J］. Modern Oncol, 2012, 20(7): 1321-1324. ［14］ Wang Y, Zhu X, Duan LL, et al. Effects of alternol on the cell proliferation and apoptosis in human hepatocellular carcinoma cells［J］. J China Med Univ, 2013, 42(11): 999-1002. ［15］ Liu LL, Chen N, Yuan X, et al. The mechanism of alteronol inhibiting the proliferation of human promyelocytic leukemia HL60 cells［J］. Yao Xue Xue Bao, 2012, 47(11): 1477-1482. ［16］ Yang F, Ran F, Guo D, et al. Alteronol induced apoptosis of human lung cancer A549 cells［J］. J Shihezhi Univ, 2013, 31(3): 12-15. ［17］ Wang C, Zhang B, Chen N, et al. Alteronol induces differentiation of melanoma b16f0 cells［J］. Recent Pat Anticancer Drug Discov, 2015, 10(1): 116-127. ［18］ Ukeda H, Kawana D, Maeda S, et al. Spectrophotometric assay for superoxide dismutase based on the reduction of highly watersoluble tetrazolium salts by xanthinexanthine oxidase［J］. Biosci Biotechnol Biochem, 1999, 63(3): 485-488. DOI: 10.1271/bbb.63.485. ［19］ Skehan P, Storeng R, Scudiero D, et al. New colorimetric cytotoxicity assay for anticancerdrug screening［J］. J Natl Cancer Inst, 1990, 82(13): 1107-1112. ［20］ Strober W. Trypan blue exclusion test of cell viability［J］. Curr Protoc Immunol, 2001, Appendix 3: Appendix 3B. DOI: 10.1002/0471142735.ima03bs21. ［21］ Schmidt M, Deschner EE, Thaler HT, et al. Gastrointestinal cancer studies in the human to nude mouse heterotransplant system［J］. Gastroenterology, 1977, 72(5 Pt 1): 829-837. ［22］ Wang Z, Wang D, Liu L, et al. Alteronol inhibits the invasion and metastasis of B16F10 and B16F1 melanoma cells in vitro and in vivo［J］. Life Sci, 2014, 98(1): 31-38. DOI: 10.1016/j.lfs.2013.12.213. ［23］ Trachootham D, Alexandre J, Huang P. Targeting cancer cells by ROSmediated mechanisms: a radical therapeutic approach?［J］. Nat Rev Drug Discov, 2009, 8(7): 579-591. DOI: 10.1038/nrd2803. ［24］ Chen J, Chen N, Chen X, et al. Comparison of the antimetastasis effect of alternol and paclitaxel［J］. Chinese Pharma Bulletin, 2011, 27(8): 1111-1115. ［25］ Li W, Yin X, Duan LL, et al. Effect of alternol on DNA topoisomerase activity［J］. J China Med Univ, 2012, 41(10): 889-891.

[1]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲. 血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.
[2]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊. 局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[3]	袁健, 黄燕华. Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[4]	陈红健, 张素青. 血清miR-24-3p、H2AFX与肝癌患者临床病理特征及术后复发的关系研究[J]. 国际肿瘤学杂志, 2024, 51(6): 344-349.
[5]	郭泽浩, 张俊旺. PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[6]	张百红, 岳红云. 新作用机制的抗肿瘤药物进展[J]. 国际肿瘤学杂志, 2024, 51(6): 354-358.
[7]	许凤琳, 吴刚. EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[8]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[9]	张蕊, 褚衍六. 基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375.
[10]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[11]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东. ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[12]	刘静, 刘芹, 黄梅. 基于SMOTE算法的食管癌放化疗患者肺部感染的预后模型构建[J]. 国际肿瘤学杂志, 2024, 51(5): 267-273.
[13]	杨琳, 路宁, 温华, 张明鑫, 朱琳. 炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[14]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝. 癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[15]	张宁宁, 杨哲, 檀丽梅, 李振宁, 王迪, 魏永志. 宫颈细胞DNA倍体分析联合B7-H4和PKCδ对宫颈癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(5): 286-291.